| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 1532 | 2019 |
| Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer YL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ... New England Journal of Medicine 383 (18), 1711-1723, 2020 | 1350 | 2020 |
| First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial P Baas, A Scherpereel, AK Nowak, N Fujimoto, S Peters, AS Tsao, ... The Lancet 397 (10272), 375-386, 2021 | 803 | 2021 |
| Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN … JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet Oncology 22 (1), 51-65, 2021 | 434 | 2021 |
| First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 S Peters, A Scherpereel, R Cornelissen, Y Oulkhouir, L Greillier, ... Annals of oncology 33 (5), 488-499, 2022 | 123 | 2022 |
| Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma R Cornelissen, JPJJ Hegmans, APWM Maat, MEH Kaijen-Lambers, ... American journal of respiratory and critical care medicine 193 (9), 1023-1031, 2016 | 110 | 2016 |
| Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma R Cornelissen, LA Lievense, AP Maat, RW Hendriks, HC Hoogsteden, ... PloS one 9 (9), e106742, 2014 | 109 | 2014 |
| Poziotinib in non–small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 trial X Le, R Cornelissen, M Garassino, JM Clarke, N Tchekmedyian, ... Journal of Clinical Oncology 40 (7), 710, 2022 | 97 | 2022 |
| Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human JGJV Aerts, PL de Goeje, R Cornelissen, MEH Kaijen-Lambers, ... Clinical Cancer Research 24 (4), 766-776, 2018 | 89 | 2018 |
| Checkpoint blockade in lung cancer and mesothelioma LA Lievense, DH Sterman, R Cornelissen, JG Aerts American journal of respiratory and critical care medicine 196 (3), 274-282, 2017 | 78 | 2017 |
| High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients L Cantini, F Pecci, DP Hurkmans, RA Belderbos, A Lanese, C Copparoni, ... European journal of cancer 144, 41-48, 2021 | 69 | 2021 |
| Pleural effusion of patients with malignant mesothelioma induces macrophage-mediated T cell suppression LA Lievense, R Cornelissen, K Bezemer, MEH Kaijen-Lambers, ... Journal of Thoracic Oncology 11 (10), 1755-1764, 2016 | 69 | 2016 |
| ID: 2908 first-line nivolumab+ ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743 P Baas, A Scherpereel, A Nowak, N Fujimoto, S Peters, A Tsao, ... Journal of Thoracic Oncology 15 (10), e42, 2020 | 66 | 2020 |
| Heterogeneity in immune cell content in malignant pleural mesothelioma J Minnema-Luiting, H Vroman, J Aerts, R Cornelissen International journal of molecular sciences 19 (4), 1041, 2018 | 64 | 2018 |
| Nintedanib in idiopathic pulmonary fibrosis: practical management recommendations for potential adverse events E Bendstrup, W Wuyts, T Alfaro, N Chaudhuri, R Cornelissen, M Kreuter, ... Respiration 97 (2), 173-184, 2019 | 55 | 2019 |
| A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after … RA Belderbos, P Baas, R Berardi, R Cornelissen, DA Fennell, ... Translational Lung Cancer Research 8 (3), 280, 2019 | 55 | 2019 |
| Virtual reality and artificial intelligence for 3-dimensional planning of lung segmentectomies AH Sadeghi, APWM Maat, YJHJ Taverne, R Cornelissen, ... JTCVS techniques 7, 309-321, 2021 | 51 | 2021 |
| LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or … T Cascone, MM Awad, JD Spicer, J He, S Lu, B Sepesi, F Tanaka, ... Annals of Oncology 34, S1295, 2023 | 45 | 2023 |
| Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell … L Noordam, MEH Kaijen, K Bezemer, R Cornelissen, LA Maat, ... Oncoimmunology 7 (12), e1474318, 2018 | 45 | 2018 |
| Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial CJ de Gooijer, V van der Noort, JA Stigt, P Baas, B Biesma, R Cornelissen, ... The Lancet Respiratory Medicine 9 (6), 585-592, 2021 | 39 | 2021 |
